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Abstract 
A case of a patient with Brugada pattern on ECG is 
presented with dubious symptoms whose management was 
guided by an electrophysiology (EP) study where programmed 
ventricular stimulation easily induced ventricular fibrillation 
with only two ventricular extrastimuli and facilitated a decision 
to implant a defibrillator for sudden death protection. Images of 
the EP tracings are provided that illustrate the findings and the 
pros and cons of such an approach are herein discussed. 
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A 51-year-old gentleman was told of a suspect 
electrocardiogram (ECG) showing Brugada pattern 7 years 
earlier when he experienced an episode of palpitations 
accompanied by dizziness and lightheadedness, but 
records were not available. Three months before this 
referral he had a febrile episode during which a recorded 
ECG was compatible with coved type I Brugada pattern. 
Other subsequent ECGs and ambulatory recordings 
showed either type I (Fig. 1) or type II Brugada pattern.  
 
Figure 1 
 
Except for this single spell of palpitations and dizziness in 
the remote past, the patient denied syncopal episodes or 
disturbed sleep. Past medical history was significant for 
smoking and hyperlipidemia treated with a statin. Physical 
examination was unrevealing. Echocardiographic 
examination was reported within normal limits.  
For further risk stratification, an electrophysiology 
study (EPS) with programmed ventricular stimulation 
(PVS) was recommended. During the EPS, a prolonged 
HV interval of 70 ms was recorded (Fig. 2), while the PVS 
 
Figure 2 
with use of double ventricular extrastimuli (coupling 
intervals 220/160 ms) at the right ventricular (RV) apex 
induced ventricular fibrillation (VF) (Fig. 3) which was 
promptly electrically cardioverted (Fig. 4). The patient 
was subsequently recommended, consented to and 
received an implantable cardioverter defibrillator (ICD) 
device for sudden cardiac death (SCD) protection. Over 
the ensuing 3 years, the patient has remained 
asymptomatic with no activation of the device as yet. 
 
Figure 3  
 
 
Figure 4 
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Symptomatic patients with spontaneous type I 
Brugada pattern (Brugada syndrome) do not require 
further risk stratification and they should have an ICD 
implanted for protection of SCD. 1, 2 However, 
asymptomatic patients or patients with equivocal 
symptoms will need further risk stratification. The role of 
PVS for risk stratification of asymptomatic Brugada 
patients remains controversial. 1, 2 Sustained VF can be 
induced in up to 40-50% of Brugada syndrome patients (up 
to 34% in asymptomatic patients vs 70% in symptomatic 
patients) (Figures 3 & 4), which is much higher than the 
induction rate encountered in normal individuals. 3, 4 
However, many factors seem to determine inducibility 
with the type and aggressiveness of the specific PVS 
protocol employed as the most important determinant; the 
number of ventricular extrastimuli (two or three), the site 
of RV pacing (RV apex and/or RV outflow tract), the 
minimal coupling interval of the extrasystoles, induction 
attempts and drive cycle lengths employed (two or three), 
and the autonomic nervous system status of the patient, all 
play a significant role in VF inducibility. The more 
aggressive the protocol the higher the rate of inducible VF 
and thus the lower the specificity of the test. Other 
important pertinent questions relate to the value and 
clinical utility of a negative test; does it identify truly low-
risk patients? 5 A two-extra-stimuli PVS protocol would 
probably be the most conservative approach for risk 
stratification. 1, 2, 6 What about reproducibility? If a patient 
has inducible VF with use of 3 extrastimuli, should one 
accept the result as positive or should one proceed to test 
for reproducibility and only if reproducible accept it as true 
positive? Finally, should one take into account other 
findings of the EPS in addition to VF inducibility, like 
refractory periods, 3 sinus node dysfunction and/or 
prolonged HV interval suggestive of conduction 
disturbance. Thus, all these issues have not been settled.  
In the FINGER registry of 1029 (654 asymptomatic) 
patients, a higher event rate was found in patients with 
inducible ventricular arrhythmia (VA) (both symptomatic 
and asymptomatic), which was nonsignificant on 
multivariate analysis, with an overall low incidence of 
0.5% (cardiac event rate) in asymptomatic patients. 7 
Similarly, in the PRELUDE registry of 308 Brugada 
patients (273 asymptomatic), there was no significant 
difference in event rates between patients with inducible 
and noninducible VAs. 3 However, in the study by Brugada 
brothers, inducibility was a powerful predictor of 
arrhythmic events during follow-up; 60 (28%) of 217 
inducible patients had spontaneous VF compared with 5 
(2%) of 221 noninducible patients (P = 0.0001). 4 Their 
PVS protocol included a minimum of two basic pacing 
cycle lengths with two extrasystoles from the RV apex.  
 
A systematic review and pooled analysis of 8 studies 
comprising 1312 patients evaluating the role of PVS (527 
with induced arrhythmia with up to 3 extrastimuli) in 
identifying patients with Brugada syndrome at the highest 
risk for SCD, indicated that induction was associated with 
cardiac events during follow-up (hazard ratio, 2.66, 
P<0.001), with the greatest risk observed among those 
induced with single or double extrastimuli. 8 The lowest 
risk occurred in individuals without syncope and with 
drug-induced type 1 patterns (0.23% for no induced 
arrhythmia with up to double extrastimuli; 0.45% for 
induced arrhythmia), and the highest risk occurred in 
individuals with syncope and spontaneous type 1 patterns 
(2.55%, for no induced arrhythmia; 5.60%, for induced 
arrhythmia). The authors concluded that in patients with 
Brugada syndrome, arrhythmias induced with PVS are 
associated with future VA risk. Induction with fewer 
extrastimuli is associated with higher risk. However, 
clinical risk factors are important determinants of 
arrhythmia risk, and lack of induction does not necessarily 
portend low VA risk, particularly in patients with high-risk 
clinical features. 
 In a most recent meta-analysis of 6 studies including 
1138 asymptomatic patients with Brugada syndrome, of 
the patients with inducible VA at EPS (n=390 or 34.3%), 
13 total arrhythmic events occurred (3.3% of the patients 
with inducible VA). 9 In asymptomatic patients with 
Brugada syndrome, 748 patients did not have inducible 
VA at EPS. There were 12 total arrhythmic events in this 
population (1.6% of the patients with noninducible VA). 
This results in an odds ratio (OR) of 2.3 (p=0.20) for major 
arrhythmic events in asymptomatic patients with Brugada 
syndrome and inducible VA at EPS. A recent pooled 
analysis of 4 studies assessing risk stratification in 1338 
Brugada patients indicated that a spontaneous type-1 
Brugada pattern on the ECG is associated with a worse 
prognosis when combined with positive EPS, 10 which fits 
the description of our case presented herein. Hence, EPS 
served as the most decisive tool in risk stratification in our 
patient.  
 In summary, in view of a lack of other reliable risk 
stratifiers in Brugada patients who do not have or have 
doubtful symptoms, as in our case, the suggestion to 
perform an EPS practically finds no rival in risk 
stratification tools to use for these patients. The question 
remains about the type of specific PVS protocol to employ 
during the EPS, however, induction of VF with up to two 
extrastimuli, as in our case, is met with general agreement 
57 
 
 
as an acceptable guide to recommend ICD implantation ; 
in cases of VF induced with three extrastimuli, one may 
consider repeating the stimulation for purpose of 
reproducibility, however, this remains speculative.  
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